NCT06169215 2026-05-13Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaNational Cancer Institute (NCI)Phase 2 Active not recruiting70 enrolled